Memphasys Aktie
Memphasys Ltd Unternehmensprofil
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the companys product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port. Further, it provides ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Vorstand
Herr Pablo Neyertz
Direktor für Finanzen
Prof. R. John Aitken Ph.D., ScD FRSE
Wissenschaftlicher Direktor
Herr Stefan Ross
Gesellschaftssekretär
Aktionärsstruktur
47,314%
Freefloat
46,94%
Individuelle Aktionäre
0,374%
Institutionelle Aktionäre
Termine
Stammdaten
| Nennwert/Aktie | - |
| Land | Australien |
| Währung | AUD |
| Branche | Biotechnologie |
| Aktientyp | - |
| Sektor | Gesundheit |
| Gattung | - |
Quelle: Leeway